A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
National Institute of Allergy and Infectious Diseases (NIAID)
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug
therapy, some patients will reject their new kidney. This study is designed to test two
anti-rejection approaches. Two medications in this study are currently used in children, but
there is no information regarding which drug is safer or more effective.
Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for
an improved post-transplant treatment, such as the induction therapy used in this study.
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
Wyeth is now a wholly owned subsidiary of Pfizer
To assess equivalence in the rates of functional graft survival at 12 months after
transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune,
Neoral) and sirolimus versus induction with CsA and sirolimus followed by CsA elimination
and concentration-controlled sirolimus.
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
M.D. Anderson Cancer Center
Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk
myelodysplastic syndromes (MDS).
Secondary: To evaluate response duration, survival and side effects of the treatment.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.